New drug shows promise in battle against rare blood cancer
Disease control
Recruiting now
This study compares a new drug, pacritinib, to the standard drug hydroxyurea for adults with advanced chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib controls the disease better and causes fewer side effects. Participants will be randomly assigned to take…
Phase: PHASE2 • Sponsor: Theradex • Aim: Disease control
Last updated May 11, 2026 20:39 UTC